1. Home
  2. CINF vs BIIB Comparison

CINF vs BIIB Comparison

Compare CINF & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cincinnati Financial Corporation

CINF

Cincinnati Financial Corporation

HOLD

Current Price

$164.66

Market Cap

25.2B

Sector

Finance

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$177.04

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CINF
BIIB
Founded
1950
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.2B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
CINF
BIIB
Price
$164.66
$177.04
Analyst Decision
Strong Buy
Buy
Analyst Count
4
22
Target Price
$174.50
$177.40
AVG Volume (30 Days)
518.7K
2.4M
Earning Date
02-09-2026
02-11-2026
Dividend Yield
2.11%
N/A
EPS Growth
N/A
N/A
EPS
13.44
10.97
Revenue
$12,078,000,000.00
$10,065,900,000.00
Revenue This Year
$10.47
$3.58
Revenue Next Year
N/A
N/A
P/E Ratio
$12.26
$16.14
Revenue Growth
N/A
4.77
52 Week Low
$123.02
$110.04
52 Week High
$169.86
$185.17

Technical Indicators

Market Signals
Indicator
CINF
BIIB
Relative Strength Index (RSI) 50.25 57.52
Support Level $164.93 $168.56
Resistance Level $168.17 $177.18
Average True Range (ATR) 2.48 4.78
MACD -0.17 -0.81
Stochastic Oscillator 55.26 58.78

Price Performance

Historical Comparison
CINF
BIIB

About CINF Cincinnati Financial Corporation

Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The company operates in segments: Commercial lines insurance, Personal lines insurance, and Excess and surplus lines insurance, Life insurance, and Investments. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: